Circulating tumor cell dynamic detecting to optimize neoadjuvant chemotherapy combined with liver transplantation in perihilar cholangiocarcinoma  

作　　者：Wen-Jin Liang Chen Liang Zhi-Gao Xu Shao-Jun Ye Zi-Biao Zhong Qi-Fa Ye 

机构地区：[1]Institute of Hepatobiliary Diseases,Transplant Center,Zhongnan Hospital of Wuhan University,Wuhan 430071,China [2]National Quality Control Center for Donated Organ Procurement,Wuhan 430071,China [3]Hubei Key Laboratory of Medical Technology on Transplantation,Wuhan 430071,China [4]Department of Chemoradiotherapy,Zhongnan Hospital of Wuhan University,Wuhan 430071,China

出　　处：《Hepatobiliary & Pancreatic Diseases International》2025年第2期225-227,共3页国际肝胆胰疾病杂志(英文版)

基　　金：supported by grants from the National Natural Science Foundation of China(82103615);National Natu-ral Science Foundation of Hubei Province(2024AFB772);Transla-tional Medicine Project of Health Commission of Hubei Province(ZHYX2021002);Discipline Platform Support Project of Zhong-nan Hospital of Wuhan University(PTXM2023022,and 2023CGZH-MS010)。

摘　　要：To the Editor:Perihilar cholangiocarcinoma(PHCCA)is the most well-known biliary malignancy,representing around 60%of all bile duct cancers[1].As of now,radical resection is the only possible means to cure PHCCA patients.The median survival time of patients undergoing radical resection can exceed 40 months,and the overall survival rate at 5 years after surgery is 25%to 67%,while the median survival time of patients who cannot be resected is only 10 to 12 month[2].

关 键 词：HILAR PATIENTS SURGERY 

分 类 号：R735.8[医药卫生—肿瘤]